Snyder Alexandra
Präsident bei Merck, Inc.
Profil
Alexandra Snyder is a Principal at Two River.
Prior to joining Two River, Dr. Snyder was Associate Vice President of Global Clinical development at Merck, Inc, where she led Translational Oncology.
She was responsible for clinical trial execution, biomarkers, companion diagnostics, and quantitative pharmacology for Oncology.
Dr. Snyder featured frequently in FDA interactions about personalized medicine; her expertise in tumor genomics and neoantigens played a pivotal role in the approval of Keytruda (pembrolizumab) for tumor mutation burden-high tumors.
Before joining Merck, Dr. Snyder was Translational Medicine Lead at Adaptive Biotechnologies, a biotechnology company that develops T cell receptor-based diagnostics and therapeutics.
During her academic career, Dr. Snyder led clinical trials and a translational laboratory at Memorial Sloan Kettering Cancer Center (MSKCC).
Dr. Snyder received her B.A.
from Princeton University, her M.D.
from Mount Sinai School of Medicine, Internal Medicine training at Mount Sinai Hospital and Fellowship at MSKCC.
Dr. Snyder is a board-certified medical oncologist and serves as voluntary faculty at Bellevue Hospital and NYU.
Aktive Positionen von Snyder Alexandra
| Unternehmen | Position | Beginn |
|---|---|---|
Two River Group Holdings LLC
 Two River Group Holdings LLC Investment ManagersFinance Two River Group Holdings LLC is a venture capital firm founded in 2004 by David M.Tanen, Joshua A.Kazam and Ben Bernstein. The firm is headquartered in New York. | Private Equity Investor | 01.08.2021 |
Generate Biomedicines, Inc.
 Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Corporate Officer/Principal | 01.07.2022 |
| Merck, Inc. | Präsident | - |
Ausbildung von Snyder Alexandra
| Princeton University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Two River Group Holdings LLC
Two River Group Holdings LLC Investment ManagersFinance Two River Group Holdings LLC is a venture capital firm founded in 2004 by David M.Tanen, Joshua A.Kazam and Ben Bernstein. The firm is headquartered in New York. | Finance |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Health Technology |
| Merck, Inc. |
